Upload
grant-armstrong
View
220
Download
0
Tags:
Embed Size (px)
Citation preview
RISKS of NSAIDS:RISKS of NSAIDS:
Focus on GI Risks ofFocus on GI Risks ofOver-the-Counter NSAIDsOver-the-Counter NSAIDs
Byron Cryer, M.D.Byron Cryer, M.D.
University of Texas Southwestern Medical SchoolUniversity of Texas Southwestern Medical School
List of Available NSAIDs:List of Available NSAIDs:Prescription & OTC Prescription & OTC **
NON-SALICYLATESNON-SALICYLATES SALICYLATES SALICYLATES COX-2 INHIBITORSCOX-2 INHIBITORSDiclofenac (Voltaren)Diclofenac (Voltaren) Aspirin Aspirin a,ca,c (Zorprin, Easprin) (Zorprin, Easprin) Celecoxib (Celebrex)Celecoxib (Celebrex)Diclofenac/Misoprostol (Arthrotec)Diclofenac/Misoprostol (Arthrotec) Diflunisal (Dolobid)Diflunisal (Dolobid) Rofecoxib (Vioxx)Rofecoxib (Vioxx)Etodolac (Lodine)Etodolac (Lodine) Salsalate (Disalcid, Salflex)Salsalate (Disalcid, Salflex) Valdecoxib (Bextra)Valdecoxib (Bextra)Fenoprofen (Nalfon)Fenoprofen (Nalfon) Choline salicylate (Trilisate)Choline salicylate (Trilisate)Flurbiprofen (Ansaid)Flurbiprofen (Ansaid) Magnesium salicylate (Magan)Magnesium salicylate (Magan) IbuprofenIbuprofen a,b,c a,b,c (Motrin, Advil) (Motrin, Advil) Indomethacin (Indocin)Indomethacin (Indocin)KetoprofenKetoprofen a,b,ca,b,c(Orudis) (Orudis)
Ketorolac (Toradol)Ketorolac (Toradol)cc
MeclofenamateMeclofenamateMefenamic acid (Ponstel)Mefenamic acid (Ponstel)Meloxicam (Mobic)Meloxicam (Mobic)Nabumetone (Relafen)Nabumetone (Relafen)NaproxenNaproxen a,b,ca,b,c(Naprosyn, Anaprox)(Naprosyn, Anaprox)Oxaprozin (Daypro)Oxaprozin (Daypro)Piroxicam (Feldene)Piroxicam (Feldene)Sulindac (Clinoril)Sulindac (Clinoril)Tolmetin (Tolectin)Tolmetin (Tolectin)
aa Also available as Also available as OTCOTC preparations in U.S. preparations in U.S.bb OTC dose is usually OTC dose is usually halfhalf of prescribed dose of prescribed doseC C All OTC NSAIDs are All OTC NSAIDs are non-selectivenon-selective COX Inhibitors COX Inhibitors
* * List of trade names is not exhaustiveList of trade names is not exhaustive
Comments on Over-the-Counter Preparations:Comments on Over-the-Counter Preparations:
NSAIDs: What Are the Risks?NSAIDs: What Are the Risks? Prescription & OTC Prescription & OTC
GI TractGI Tract Ulcers, perforations, bleeding, obstruction strictures, Ulcers, perforations, bleeding, obstruction strictures,
enteropathy enteropathy KidneyKidney
Sodium and fluid retention Sodium and fluid retention HyperkalemiaHyperkalemia Acute renal failure Acute renal failure HypertensionHypertension
PlateletPlatelet Inhibition of aggregation leading to increased potential for Inhibition of aggregation leading to increased potential for
bleedingbleeding
Peptic Ulcer Hospitalization RatesPeptic Ulcer Hospitalization Rates
Kurata JH. Kurata JH. Semin Gastrointest DisSemin Gastrointest Dis 1993:4 1993:4
RateRate per per
100,000100,000
Gastric UlcerGastric Ulcer Duodenal UlcerDuodenal Ulcer
70 75 80 85 900
20
40
60
80
100
Uncomplicated Uncomplicated
HemorrhageHemorrhage
Perforation Perforation
70 75 80 85 900
20
40
YearYear YearYear
30
10
Uncomplicated Uncomplicated
HemorrhageHemorrhage
Perforation Perforation
Endoscopic Photograph of GastropathyEndoscopic Photograph of Gastropathy
Endoscopic PhotographEndoscopic Photographof Gastric Ulcerof Gastric Ulcer
Prevalence of EndoscopicPrevalence of EndoscopicNSAID-Induced UlcerationNSAID-Induced UlcerationPrevalence of EndoscopicPrevalence of EndoscopicNSAID-Induced UlcerationNSAID-Induced Ulceration
MeanMean RangeRangeGastric UlcerGastric Ulcer 15 % 15 % 10 to 30%10 to 30%
Duodenal UlcerDuodenal Ulcer 5 % 5 % 4 to 10 % 4 to 10 %
Clinically Significant UlcersClinically Significant Ulcers 2% 2% 1 to 4% 1 to 4%
MeanMean RangeRangeGastric UlcerGastric Ulcer 15 % 15 % 10 to 30%10 to 30%
Duodenal UlcerDuodenal Ulcer 5 % 5 % 4 to 10 % 4 to 10 %
Clinically Significant UlcersClinically Significant Ulcers 2% 2% 1 to 4% 1 to 4%
Risk Factors forRisk Factors forSerious GI Adverse Events with NSAIDs:Serious GI Adverse Events with NSAIDs: Relative RisksRelative Risks
Rodriguez. Lancet. 1994; Guttham. Epidemiology. 1997; Shorr. Arch Intern Med. 1993; Piper. Ann Intern Med. 1991.
0 5 10 15
4.4 (2.0-9.7)
12.7 (6.3-25.7)
2.9 (2.2-3.8)
5.8 (4.0-8.6)
5.6 (4.6-6.9)
3.1 (2.5-3.7)
1.6 (1.4-2.0)
13.5 (10.3-17.7)
Corticosteroid use
Anticoagulant use
Low dose NSAIDLow dose NSAID
High dose NSAID
Age 70-80
Age 60-69
Age 50-59
Prior bleed
Relative RiskRelative Risk
OTC NSAIDs: What Are the GI Risks?OTC NSAIDs: What Are the GI Risks?
OTC NSAIDS / Low-Dose AspirinOTC NSAIDS / Low-Dose Aspirin::
Non-Aspirin NSAIDsNon-Aspirin NSAIDs Low Dose Aspirin Low Dose Aspirin Non-Aspirin NSAIDs in combination with Low-Dose Non-Aspirin NSAIDs in combination with Low-Dose
Aspirin Aspirin NSAIDs plus ETOHNSAIDs plus ETOH Acetaminophen and Gastrointestinal InjuryAcetaminophen and Gastrointestinal Injury Hepatotoxicity with NSAIDs Hepatotoxicity with NSAIDs
Prevalence of NSAID Use in Patients Prevalence of NSAID Use in Patients Presenting with Upper GI BleedingPresenting with Upper GI BleedingPatient History (n = 411)
Prevalence of NSAID Use in Patients Prevalence of NSAID Use in Patients Presenting with Upper GI BleedingPresenting with Upper GI BleedingPatient History (n = 411)
Wilcox Wilcox et alet al; ; Arch Int Med Arch Int Med 1994; 154:421994; 154:42
0
10
20
30
40
50PrescribedPrescribed
OTCOTC
Non-AspirinNon-AspirinNSAIDsNSAIDs
AspirinAspirin
Percent usingPercent using
NSAIDsNSAIDs
14 %14 %7 %7 % 9 %9 %
35 %35 %
Prevalence of OTC Analgesic Use in Patients Prevalence of OTC Analgesic Use in Patients Presenting with GI BleedingPresenting with GI Bleeding
28.4
10
3.1 4.1
21.5
10.4
2.4
5.6
27.1
10.2
2.84.4
12.3
6.2
0.7
6.5
0
5
10
15
20
25
30
ASA Ibuprofen Naproxen Sodium Acetaminophen
UGI Bleeders n=482 LGI Bleeders n=125 Total Bleeders n=635 Total Controls n=600
Percent of UsePercent of Use
**
**
**
UGI UGI = upper gastrointestinal; LGI LGI = lower gastrointestinal ** p < 0.05
Peura DA et al. Am J Gastroenterol. 1997;92:924-928
NSAID Dose andNSAID Dose andRelative Risk of Upper GI ComplicationsRelative Risk of Upper GI Complications
Cases (n)
Controls (n)
Adjusted RR
95% CI
NSAID dose Low/medium High
92311
290229
2.44.9
1.9-3.14.1-5.8
Garcia Rodriguez, Hernandez-Diaz. Epidemiology. 2001;12:570-576.
Risks of GI Bleeding with Analgesics:Prescription & OTC Prescription & OTC
Blot WJ, Mclaughlin JK. J Epidemiol Biostat. 2000;5:137-142.
AnalgesicAnalgesic CaseCase ControlControl Odds RatioOdds Ratio 95% CI 95% CI n=627 n=590 (OR)
OTC use of: % % Aspirin 27.0 12.0 2.7 1.9-3.8
Ibuprofen 10.1 5.8 2.4 1.5-3.9
Acetaminophen 4.5 6.3 0.9 0.5-1.6
Total OTC NSAIDs 36.2 17.5 3.0 2.2-4.1
Rx NSAIDs 9.3 5.9 2.1 1.2-3.4
Total NSAIDS 42.9 22.0 3.1 2.3-4.1
GI Bleeding According to Dose ofGI Bleeding According to Dose ofOTC Ibuprofen UseOTC Ibuprofen Use
00
11
22
33
44
<600 mg/d<600 mg/d 600 to 1200 mg/d600 to 1200 mg/d >1200 mg/d>1200 mg/d
Od
ds
Rat
ioO
dd
s R
atio
Blot WJ, McLaughlin J. Blot WJ, McLaughlin J. J Epidemiol Biostat.J Epidemiol Biostat. 2000;5:137-142. 2000;5:137-142.
DOSEDOSE
OTC NSAID Usage Patterns OTC NSAID Usage Patterns (n=535 OTC NSAID Users)(n=535 OTC NSAID Users)
Fraction of Previous Month Respondents (%)Fraction of Previous Month Respondents (%)
< 50 < 50 9.0 9.0
50 – 7550 – 75 11.8 11.8
Having Used OTCHaving Used OTC NSAIDs (%)NSAIDs (%)
> 75> 75 79.2 79.2
Reason for Taking OTC NSAIDReason for Taking OTC NSAID Respondents (%)*Respondents (%)*
Prevention of Cardiac ProblemsPrevention of Cardiac Problems 43.2 43.2
OtherOther 9.0 9.0
HeadacheHeadache 12.3 12.3
ArthritisArthritis 24.5 24.5
General Aches & PainGeneral Aches & Pain 29.9 29.9
*Total exceeds 100 because multiple responses were allowed*Total exceeds 100 because multiple responses were allowed
Bloom BS et. al Am J Gastroenterol 2001 (abstract)
DURATIONDURATION
Relative Risk of GI Problems in the Previous 30 Days Relative Risk of GI Problems in the Previous 30 Days with OTC NSAIDSwith OTC NSAIDS
GastrointestinalGastrointestinal OTC NSAIDOTC NSAID (%) Nonusers (%) Relative (95% CI)(%) Nonusers (%) Relative (95% CI)
Any GI ProblemAny GI Problem 105 105 (19.6)(19.6) 101 101 (9.4)(9.4) 2.12.1 (1.61-2.67) (1.61-2.67)
Users (n=535)Users (n=535) (n=1,086)(n=1,086) RiskRisk
ConstipationConstipation 34 (6.3)34 (6.3) 16 (1.5) 4.5 16 (1.5) 4.5 (2.36-7.62) (2.36-7.62)
Stomach Cramps/PainStomach Cramps/Pain 18 (3.4)18 (3.4) 12 (1.1) 3.0 12 (1.1) 3.0 (1.45-6.17) (1.45-6.17)
Indigestion/HeartburnIndigestion/Heartburn 11 (2.0)11 (2.0) 10 (0.9) 2.2 10 (0.9) 2.2 (0.94-5.14) (0.94-5.14)
Abdominal Bloating/GasAbdominal Bloating/Gas 7 (1.3) 7 (1.3) 7 (0.6) 2.0 7 (0.6) 2.0 (0.70-5.66) (0.70-5.66)
DiarrheaDiarrhea 17 (3.2)17 (3.2) 26 (2.4) 1.3 26 (2.4) 1.3 (0.71-2.38) (0.71-2.38)
Nausea/VomitingNausea/Vomiting 4 (0.7) 4 (0.7) 4 (0.4) 2.0 4 (0.4) 2.0 (0.50-7.95) (0.50-7.95)
GI Bleeding/UlcerGI Bleeding/Ulcer 3 3 (0.6)(0.6) 3 3 (0.3)(0.3) 2.02.0 (0.40-9.86) (0.40-9.86)
Other ComplaintsOther Complaints 27 (5.0)27 (5.0) 33 (3.1) 1.6 33 (3.1) 1.6 (0.99-2.69) (0.99-2.69)
ComplaintComplaint
Bloom BS et. Al Am J Gastroenterol 2001 (abstract)
DURATIONDURATION
Medications Taken in the Previous 30 DaysMedications Taken in the Previous 30 Daysfor GI Problems by OTC NSAID Usersfor GI Problems by OTC NSAID Users
Medications Used inMedications Used in OTC NSAID OTC NSAID Controls Controls PP value value
Previous Month Previous Month
OTC GI Medication OTC GI Medication 24.324.3 10.3 10.3 0.001 0.001
Rx GI MedicationRx GI Medication 9.5 9.5 5.2 5.2 0.001 0.001
Users (n=535)(%)Users (n=535)(%)
OTC and RX GI MedicationOTC and RX GI Medication 2.1 2.1 1.3 1.3 NS NS
Bloom BS et. al Am J Gastroenterol 2001 (abstract)
(n=1,068)(%)(n=1,068)(%)
OTC NSAIDs: What Are the GI Risks?OTC NSAIDs: What Are the GI Risks?
OTC NSAIDS / Low-Dose AspirinOTC NSAIDS / Low-Dose Aspirin::
Non-Aspirin NSAIDsNon-Aspirin NSAIDs Low Dose AspirinLow Dose Aspirin Non-Aspirin NSAIDs in combination with Low-Dose Non-Aspirin NSAIDs in combination with Low-Dose
Aspirin Aspirin NSAIDs plus ETOHNSAIDs plus ETOH Acetaminophen and Gastrointestinal InjuryAcetaminophen and Gastrointestinal Injury Hepatotoxicity with NSAIDs Hepatotoxicity with NSAIDs
Odds Ratio of Upper GI BleedingOdds Ratio of Upper GI BleedingIn Patients Taking NSAIDSIn Patients Taking NSAIDS
FACTORFACTOR
History of gastrointestinal bleedingHistory of gastrointestinal bleeding
History of ulcerHistory of ulcer
Aspirin at any doseAspirin at any dose
NitrovasodilatorNitrovasodilator
Antisecretory medicationAntisecretory medication
PatientsPatients(N=317)
37 (11.7)
69 (21.8)
73 (23.0)
11 (3.5)(3.5)
29 (9.1)
ControlsControls(N=187)
6 (3.4)
18 (9.6)
18 (9.6)
11 (5.9)(5.9)
37 (19.8)
AdjustedAdjustedOdds RatioOdds Ratio
(96% CI)
3.7 (1.2-1.1)
1.8 (0.9-3.6)
3.1 (1.7-5.9)
0.3 (0.1-0.9)
0.4 (0.2-0.7)
PPValueValue
0.01
0.09
<0.001
0.04
0.001
Number (%)Number (%)
Lanas A., Lanas A., et al. N Engl J Med 2000; 343:834-839. N Engl J Med 2000; 343:834-839
Prior Placebo-Controlled Study of Low Dose Prior Placebo-Controlled Study of Low Dose ASA for Prevention of Cerebrovascular EventsASA for Prevention of Cerebrovascular Events
0
10
20
30
40
13132121
3838
**
*
Placebo
( n = 814 )
300 mg Q D
( n = 806 )
1200 mg Q D
( n = 815 )
Number of Number of Patients with Patients with G.I. BleedingG.I. Bleeding
ASA DoseASA DoseBMJ 1988 ;296:316
Risk of Acute Major UGIB According to Use of Aspirin Risk of Acute Major UGIB According to Use of Aspirin and Ibuprofen in the Week Before and Ibuprofen in the Week Before
Kaufman DW, Kelly JP, Wilholm BE, et al. Kaufman DW, Kelly JP, Wilholm BE, et al. Am J GastroenterolAm J Gastroenterol. 1999;94:3189-3196.. 1999;94:3189-3196.
Daily Aspirin Dose andDaily Aspirin Dose andAdmission for Ulcer BleedingAdmission for Ulcer Bleeding
Aspirin Dose
75 mg (n=27)
150 mg (n=22)
300 mg (n=62)
Odds Ratio (95% Cl)
2.3 (1.2-4.4)
3.2 (1.7-6.5)
3.9 (2.5-6.3)
Weil J et al. BMJ. 1995;310:827-830.
Mechanisms of NSAID/ Aspirin-induced Mechanisms of NSAID/ Aspirin-induced Mucosal InjuryMucosal Injury
Alterations in gastric mucosal barrier
Prostaglandin synthesis
Mucus and bicarbonate secretion
Submucosal blood flow
Mucosal ATP
Cell turnover
Platelet function (irreversible)
Ivey KJ. Am J Med. 1988;84:41-48.
Prostaglandin synthesisProstaglandin synthesis
Effect of Aspirin Doses on Effect of Aspirin Doses on Gastrointestinal ProstaglandinsGastrointestinal Prostaglandins
Percent of
Baseline
( p < 0.05 vs. Baseline )*Stomach Duodenum Rectum
* * * * **
Baseline
0
20
40
60
80
100
120
10 mg ASA
81 mg ASA
325 mg ASA
Cryer, et al. Gastroenterology 1999;117:17-25.Cryer, et al. Gastroenterology 1999;117:17-25.
Risk of UGI bleeding with Different Formulations Risk of UGI bleeding with Different Formulations of Low-Dose Aspirin (< 325mg)of Low-Dose Aspirin (< 325mg)
0
43.6
2.62.4
2.62.6
Relative RiskRelative Risk
Gastric bleeding Duodenal bleeding
3.2
Plain ASA
Coated ASA
Buffered ASA
550 cases of UGIB admitted to hospital with melena or confirmed hematemesis
Kelley et al, Lancet 1996; 348; 1413
Lansoprazole (30 mg QD) + aspirin (100 mg daily) orLansoprazole (30 mg QD) + aspirin (100 mg daily) or Aspirin alone (100 mg daily) for 12 months.Aspirin alone (100 mg daily) for 12 months.
Recurrence of Bleeding Ulcers at 12 months
1.6%
14.8%
0%
20% Aspirin + lansoprazole (n=62)
Aspirin (n=61)
Lai et al, N Engl J Med 2002; 346: 2033Lai et al, N Engl J Med 2002; 346: 2033
Effect of Proton Pump Inhibitor on Upper GI Effect of Proton Pump Inhibitor on Upper GI Injury with Low-Dose AspirinInjury with Low-Dose Aspirin
OTC NSAIDs: What Are the GI Risks?OTC NSAIDs: What Are the GI Risks?
OTC NSAIDS / Low-Dose AspirinOTC NSAIDS / Low-Dose Aspirin::
Non-Aspirin NSAIDsNon-Aspirin NSAIDs Low Dose Aspirin Low Dose Aspirin Low-Dose AspirinLow-Dose Aspirin in combination with Non-Aspirin in combination with Non-Aspirin
NSAIDs NSAIDs NSAIDs plus ETOHNSAIDs plus ETOH Acetaminophen and Gastrointestinal InjuryAcetaminophen and Gastrointestinal Injury Hepatotoxicity with NSAIDs Hepatotoxicity with NSAIDs
• National cohort study in DenmarkNational cohort study in Denmark
• 27,694 people on aspirin 100-150 mg qd27,694 people on aspirin 100-150 mg qd
Treatment regimenTreatment regimenIncreased incidenceIncreased incidence
over generalover generalpopulation population
95% CI95% CI
Low-dose aspirin
Low-dose aspirin + NSAIDs
2.6
5.6
2.2 - 2.9
4.4 - 7.0
Sorensen et al, Am J Gastroenterol 2000; 95; 2218
Risk of Combining Low-Dose Aspirin Risk of Combining Low-Dose Aspirin with NSAIDswith NSAIDs
Ann
ualiz
ed I
ncid
ence
%
Ulcer ComplicationsUlcer Complications Symptomatic Ulcers andSymptomatic Ulcers andUlcer ComplicationsUlcer Complications
0
1
2
3
4
5
6
49 / 138449 / 1384
30 / 144130 / 1441
11 / 144111 / 144120 / 138420 / 1384
p = 0.02p = 0.02
p = 0.09p = 0.09All PatientsAll Patients
0
1
2
3
4
5
6
32 / 110132 / 1101
16 / 114316 / 11435 / 11435 / 1143
14 / 110114 / 1101
p = 0.02p = 0.02
p = 0.04p = 0.04Patients Not Taking AspirinPatients Not Taking Aspirin
0
1
2
3
4
5
6 17 / 28317 / 283
14/ 29814/ 298
6 / 2986 / 298 6 / 2836 / 283
p = 0.49p = 0.49
p = 0.92p = 0.92
Patients Taking AspirinPatients Taking Aspirin
CLASS Trial: Upper GI ComplicationsCLASS Trial: Upper GI ComplicationsAlone and With Symptomatic UlcersAlone and With Symptomatic Ulcers
Silverstein et al. JAMA 2000; 284:1247-1255
= celecoxib= celecoxib= NSAIDs (ibuprofen + diclofenac)= NSAIDs (ibuprofen + diclofenac)
OTC NSAIDs: What Are the GI Risks?OTC NSAIDs: What Are the GI Risks?
OTC NSAIDS / Low-Dose AspirinOTC NSAIDS / Low-Dose Aspirin::
Non-Aspirin NSAIDsNon-Aspirin NSAIDs Low Dose Aspirin Low Dose Aspirin Non-Aspirin NSAIDs in combination with Low-Dose Non-Aspirin NSAIDs in combination with Low-Dose
Aspirin Aspirin NSAIDs plus ETOHNSAIDs plus ETOH Acetaminophen and Gastrointestinal InjuryAcetaminophen and Gastrointestinal Injury Hepatotoxicity with NSAIDs Hepatotoxicity with NSAIDs
Risk Factors for GI BleedingRisk Factors for GI Bleeding
Risk FactorRisk Factor Cases (n)Cases (n) Controls (n)Controls (n) OR (95% CI)
Neither factor 284 411
Alcohol 107 75 2.07 (1.48-2.88)
OTC ASA/NSAID 160 84 2.76 (2.03-3.74)
OTC ASA/NSAID plus alcohol
71 23 4.47 (2.73-7.32)
Peura DA et al. Am J Gastroenterol. 1997;92:924-928.
Relative Risks of Upper Gastrointestinal Relative Risks of Upper Gastrointestinal BleedingBleeding
Ibuprofen (95% CI)Ibuprofen (95% CI)
Aspirin (95% CI)Aspirin (95% CI)
RegularUse
Occasional Use
RegularUse> 325 mg
RegularUse325 mg
OccasionalUse
ETOH USERETOH USER 2.7 (1.6-4.4) 1.2 (0.8-1.7) 7.0 (5.2-9.3) 2.8 (2.0-3.8) 2.4 (1.9-3.0)
Never-drinkerNever-drinker 2.2 (0.8-6.0) 1.0 (0.4-2.4) 5.1 (2.8-9.0) 2.2 (1.2-4.1) 1.4 (0.8-2.6)
Kaufmann et al., Am J Gastroenterol 1999;94:3189-3196.
OTC NSAIDs: What Are the GI Risks?OTC NSAIDs: What Are the GI Risks?
OTC NSAIDS / Low-Dose AspirinOTC NSAIDS / Low-Dose Aspirin::
Non-Aspirin NSAIDsNon-Aspirin NSAIDs Low Dose Aspirin Low Dose Aspirin Non-Aspirin NSAIDs in combination with Low-Dose Non-Aspirin NSAIDs in combination with Low-Dose
Aspirin Aspirin NSAIDs plus ETOHNSAIDs plus ETOH Acetaminophen and Gastrointestinal InjuryAcetaminophen and Gastrointestinal Injury Hepatotoxicity with NSAIDs Hepatotoxicity with NSAIDs
Relative Risk of Upper GI ComplicationsRelative Risk of Upper GI Complications
Cases (n)
Controls (n)
Adjusted RR
95% CI
Acetaminophen (mg)
<1000 1001-1999 2000 2001-3999 4000
14259847813
610242127837
1.00.81.93.46.5
0.8-1.20.6-1.11.4-2.62.4-4.8
2.4-17.6
NSAID dose Low/medium High
92311
290229
2.44.9
1.9-3.14.1-5.8
Garcia-Rodriguez, Hernandez-Diaz. Epidemiology. 2001;12:570-576.
GI Bleeding Associated with AnalgesicsGI Bleeding Associated with Analgesics
Blot WJ, Mclaughlin JK. J Epidemiol Biostat. 2000;5:137-142.
AnalgesicAnalgesic CaseCase ControlControl Odds RatioOdds Ratio 95% CI 95% CI n=627 n=590 (OR)
OTC use of: % %Aspirin 27.0 12.0 2.7 1.9-3.8
Ibuprofen 10.1 5.8 2.4 1.5-3.9
Acetaminophen 4.5 6.3 0.9 0.5-1.6
Total OTC NSAIDs 36.2 17.5 3.0 2.2-4.1
Rx NSAIDs 9.3 5.9 2.1 1.2-3.4
Total NSAIDS 42.9 22.0 3.1 2.3-4.1
Drug Concentration (Drug Concentration (M)M)
Mean Percent Mean Percent Inhibition of GastricInhibition of Gastric
Mucosal PGEMucosal PGE22
00 0.010.01 0.10.1 11 1010 100100
00
2020
4040
6060
8080
100100
AcetaminophenAcetaminophen
RofecoxibRofecoxib
CelecoxibCelecoxib
NaproxenNaproxen
Cmax
Cmax
Cmax
Cmax
Effects of NSAIDs and Acetaminophen Effects of NSAIDs and Acetaminophen on Gastric Mucosaon Gastric Mucosa
Cryer, B and Feldman, M. (Abstract in press Am J Gastro)
OTC NSAIDs: What Are the GI Risks?OTC NSAIDs: What Are the GI Risks?
OTC NSAIDS / Low-Dose AspirinOTC NSAIDS / Low-Dose Aspirin::
Non-Aspirin NSAIDsNon-Aspirin NSAIDs Low Dose Aspirin Low Dose Aspirin Non-Aspirin NSAIDs in combination with Low-Dose Non-Aspirin NSAIDs in combination with Low-Dose
Aspirin Aspirin NSAIDs plus ETOHNSAIDs plus ETOH Acetaminophen and Gastrointestinal InjuryAcetaminophen and Gastrointestinal Injury Hepatotoxicity with NSAIDsHepatotoxicity with NSAIDs
Hepatotoxicity with NSAIDsHepatotoxicity with NSAIDs• Compared with other classes of drugs, hepatotoxicity with NSAIDs Compared with other classes of drugs, hepatotoxicity with NSAIDs is uncommon.is uncommon.
• Mild increases in liver testsMild increases in liver tests 1% (most NSAIDs)1% (most NSAIDs)
15% (diclofenac)15% (diclofenac)
• Clinically apparent hepatotoxicity is rare.Clinically apparent hepatotoxicity is rare. Exception = Bromfenac sodium (Duract Exception = Bromfenac sodium (Duract TMTM))
• Mechanism of toxicity with NSAIDs is Mechanism of toxicity with NSAIDs is idiosyncratic reactionidiosyncratic reaction (not (not related to dose or duration) rather than intrinsic hepatotoxicityrelated to dose or duration) rather than intrinsic hepatotoxicity
OTC NSAIDsOTC NSAIDs::Ibuprofen:Ibuprofen: rarerareNaproxen:Naproxen: rarerareKetoprofen:Ketoprofen: rarerareAspirin:Aspirin: rare but some intrinsic hepatotoxicityrare but some intrinsic hepatotoxicity
Hepatotoxicity with NSAIDsHepatotoxicity with NSAIDsAspirinAspirin::
• Some intrinsic hepatotoxicitySome intrinsic hepatotoxicity
• Injury related to:Injury related to:
DoseDose: rare at 325 mg/day or less: rare at 325 mg/day or less
DurationDuration::
– Typically at least Typically at least 6 days6 days duration of duration of high doseshigh doses in in patients with inflammatory conditions (eg., RA, SLE)patients with inflammatory conditions (eg., RA, SLE)
• Reye’s Syndrome:
– Dose-related:Dose-related:
– Median Dose = 25 mg/kgMedian Dose = 25 mg/kg
– However, risk increases 7-fold at 15 mg/kg/dayHowever, risk increases 7-fold at 15 mg/kg/day(650 mg/day for 40 kg child)(650 mg/day for 40 kg child)
– Aspirin should be avoided in children with respiratory Aspirin should be avoided in children with respiratory illness or varicella.illness or varicella.
SummarySummary
• OTC NSAIDs are associated with some GI risksOTC NSAIDs are associated with some GI risks• GI Risks of OTC NSAIDs include upper and lower GI bleedingGI Risks of OTC NSAIDs include upper and lower GI bleeding• Risk appears to be related to NSAID dose.Risk appears to be related to NSAID dose.• Much of GI risks associated with OTC NSAIDs is related to Much of GI risks associated with OTC NSAIDs is related to
aspirin, even at low-dose.aspirin, even at low-dose.• Low-dose aspirin combined with NSAID increases risks 2-4 Low-dose aspirin combined with NSAID increases risks 2-4
fold.fold.• Enteric-coated and buffered aspirin do not reduce risk.Enteric-coated and buffered aspirin do not reduce risk.• Hepatotoxicity with OTC NSAIDs and Low-Dose Aspirin is Hepatotoxicity with OTC NSAIDs and Low-Dose Aspirin is
rare.rare.